# A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis

> **NCT01483599** · PHASE2 · COMPLETED · sponsor: **Janssen Inc.** · enrollment: 293 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** CNTO 1959 (5 mg)
- **DRUG:** CNTO 1959 (15 mg)
- **DRUG:** CNTO 1959 (50 mg)
- **DRUG:** CNTO 1959 (100 mg)
- **DRUG:** CNTO 1959 (200 mg)
- **DRUG:** Adalimumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01483599
- **Lead sponsor:** Janssen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-10
- **Primary completion:** 2012-11-27
- **Final completion:** 2013-08-05
- **Target enrollment:** 293 (ACTUAL)
- **Last updated:** 2017-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01483599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01483599, "A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01483599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*